IL205246A0 - Methods and compositions for diagnostic use in cancer patients - Google Patents

Methods and compositions for diagnostic use in cancer patients

Info

Publication number
IL205246A0
IL205246A0 IL205246A IL20524610A IL205246A0 IL 205246 A0 IL205246 A0 IL 205246A0 IL 205246 A IL205246 A IL 205246A IL 20524610 A IL20524610 A IL 20524610A IL 205246 A0 IL205246 A0 IL 205246A0
Authority
IL
Israel
Prior art keywords
compositions
methods
cancer patients
diagnostic use
diagnostic
Prior art date
Application number
IL205246A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL205246A0 publication Critical patent/IL205246A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
IL205246A 2007-11-09 2010-04-22 Methods and compositions for diagnostic use in cancer patients IL205246A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688407P 2007-11-09 2007-11-09
PCT/US2008/082456 WO2009061800A2 (en) 2007-11-09 2008-11-05 Methods and compositions for diagnostic use in cancer patients

Publications (1)

Publication Number Publication Date
IL205246A0 true IL205246A0 (en) 2010-12-30

Family

ID=40342593

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205246A IL205246A0 (en) 2007-11-09 2010-04-22 Methods and compositions for diagnostic use in cancer patients

Country Status (13)

Country Link
US (2) US20090123930A1 (https=)
EP (1) EP2222874A2 (https=)
JP (1) JP2011502513A (https=)
KR (1) KR20100095571A (https=)
CN (1) CN101910416A (https=)
AU (1) AU2008324782A1 (https=)
BR (1) BRPI0817158A2 (https=)
CA (1) CA2703258A1 (https=)
IL (1) IL205246A0 (https=)
MX (1) MX2010005057A (https=)
RU (1) RU2010123381A (https=)
WO (1) WO2009061800A2 (https=)
ZA (1) ZA201002808B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482715A (zh) * 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物
AU2010297344A1 (en) * 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
EP2848939A1 (en) * 2010-07-19 2015-03-18 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CA2804246A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
RU2015102026A (ru) * 2012-06-26 2016-08-10 Ф.Хоффманн-Ля Рош Аг Биомаркеры в плазме крови для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы
MX2015006955A (es) * 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
SG11201602019XA (en) * 2013-09-17 2016-04-28 Agency Science Tech & Res Multigene assay for prognosis of renal cancer
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
KR101903522B1 (ko) * 2015-11-25 2018-11-23 한국전자통신연구원 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치
TW202528738A (zh) * 2023-11-09 2025-07-16 昇捷生物科技股份有限公司 基於α-1抗胰蛋白酶生物標記物之癌症檢測方法及套組

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
CA2604549A1 (en) * 2005-04-13 2006-10-19 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
WO2007123722A2 (en) * 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Also Published As

Publication number Publication date
EP2222874A2 (en) 2010-09-01
US20090123930A1 (en) 2009-05-14
CN101910416A (zh) 2010-12-08
WO2009061800A2 (en) 2009-05-14
RU2010123381A (ru) 2011-12-20
ZA201002808B (en) 2011-07-27
US20110151468A1 (en) 2011-06-23
JP2011502513A (ja) 2011-01-27
BRPI0817158A2 (pt) 2015-04-14
AU2008324782A1 (en) 2009-05-14
MX2010005057A (es) 2010-05-19
CA2703258A1 (en) 2009-05-14
WO2009061800A3 (en) 2009-07-16
KR20100095571A (ko) 2010-08-31

Similar Documents

Publication Publication Date Title
IL213410A0 (en) Methods and compositions for diagnostic use in cancer patients
IL205246A0 (en) Methods and compositions for diagnostic use in cancer patients
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
PL2200431T3 (pl) Nowe kompozycje i metody służące leczeniu raka
SI2173379T1 (sl) Sestavki in postopki za zdravljenje in diagnosticiranje raka
EP2129284A4 (en) IMAGING AND TOOLS FOR USE WITH MOBILE ORGANS
ZA201006941B (en) Compositions and methods for skin care
GB0708761D0 (en) Improvements in and relating to medical instruments
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
IL217748A0 (en) Methods and compositions for diagnostics use in cancer patients
PL2320900T3 (pl) Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych
GB2459076B (en) Improvements in and relating to medical devices
EP2342559A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING ARTIFACTS IN TISSUE SAMPLES
IL206189A0 (en) Compound for use in the treatment of cancer
EP2018178A4 (en) ADMINISTRATION OF AN AGONIST-ANTAGONIST COMPLEX TO PATIENTS WITH OPIOID DEPENDENCE
GB0821335D0 (en) Compositions and methods for reducing macrovascular complications in diabetic patients
GB2467494B (en) Materials and methods for medical imaging
GB0813352D0 (en) Cancer treatment and test
GB2441116B (en) Improvements in and relating to medical apparatus
GB0605209D0 (en) Examination chair
LT3067054T (lt) Naujos kompozicijos ir būdai vėžiui gydyti
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
GB0605738D0 (en) Novel diagnostic and therapeutic methods
GB0620067D0 (en) Lung cancer diagnosis and treatment thereof